Drug intelligence / Profile preview

LON-22

Development stage: Preclinical
Lead developer: ONESTX
Modality: Small Molecules
Administration: Oral

Overview

LON-22 is an early-stage preclinical combination therapy developed by ONESTX for the treatment of neurodegeneration. It consists of the small molecule steroid sulfatase (STS) inhibitor STX64 (irosustat) and neurosteroids. The therapeutic approach focuses on modulating the biology of sulfated neurosteroids; by inhibiting the STS enzyme, the drug regulates the conversion of sulfated steroids into their non-sulfated counterparts, which is hypothesized to provide neuroprotective effects in neurodegenerative conditions.

Other names: STX64 + NS

Targets

STS (Steroid sulfatase)

Beyond the preview

Go deeper on LON-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LON-22.

Explore the full profile